November 2009
BioWorld Insight;11/30/2009, Vol. 17 Issue 48, p5
The article offers world news briefs related to pharmaceutical companies. Antibody-drug conjugate collaboration of Seattle Genetics Inc. with Agensys Inc. have been expanded. BioCryst Pharmaceuticals Inc. priced 49 million dollars in their public stock offering. Novavax Inc. plans to raise their stock offering to 21 million dollars. Oxagen Ltd. had raised their Series C financing to 26.4 million dollars.


Related Articles

  • Seattle Genetics Gets $12M Up Front in Agensys ADC Deal.  // BioWorld Today;11/24/2009, Vol. 20 Issue 227, p2 

    The article reports on an upfront payment received by Seattle Genetics through an antibody-drug conjugate (ADC) collaboration with Agensys Inc. Under the agreement, Agensys will be able to obtain exclusive ADC licenses from Seattle Genetics. An expansion of the collaboration will also entitle...

  • Seattle Genetics Announces Tenth Collaborator ADC Program in Clinical Development.  // Biomedical Market Newsletter;5/14/2011, p259 

    The article focuses on clinical developments taking place on Seattle Genetics Inc.'s proprietary antibody-drug conjugate (ADC) technology. Various collaborator ADCs in clinical developments include six by Genentech Inc., and one each by Agensys Inc.. Chief Business Officer of Seattle Eric L....

  • Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer.  // Biomedical Market Newsletter;6/7/2012, Vol. 21, p1 

    The article provides information on the phase I clinical trial of the drug ASG-5ME for the treatment of castration-resistant prostate cancer being co-developed by Agensys Inc. and Seattle Genetics Inc. ASG-5ME is an antibody-drug conjugate that targets the SLC44A4 antigen. The phase I clinical...

  • Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing Collaboration.  // Biomedical Market Newsletter;6/19/2011, p1280 

    The article reports on the collaboration agreement by Seattle Genetics Inc. with Agensys Inc. and Astellas Pharma Inc. to co-develop a second antibody-drug conjugate (ADC), known as ASG-22ME, formerly AGS-22M6E. It states that ASG-22ME is an ADC composed of human antibody directed to Nectin-4...

  • Conjugal Bliss? Another Partner Favors SeaGen Approach: GSK. Osborne, Randy // BioWorld Today;12/22/2009, Vol. 20 Issue 245, p1 

    The article reports on a deal signed by Seattle Genetics Inc. with GlaxoSmithKline plc (GSK). Under the deal, GSK will pay 12 million U.S. dollar up front and 390 million U.S. dollar in milestone payments, for the research, product development, manufacturing and commercialization of the...

  • NEXT-GEN ADCS: Collaborating to Improve Supply Chains for Development and Technology Transfer with Novel Technology Platforms. Wooge, Cynthia; Swamy, Jyothi // Contract Pharma;Nov/Dec2014, Vol. 16 Issue 9, p50 

    The article discusses developments in the global pharmaceutical industry as of late 2014, particularly the issues in the supply chain for antibody-drug conjugates (ADC). It cites the two ADCs offered in the market, namely, the Adcetris (brentuximab vedotin) from Seattle Genetics for Hodgkin...

  • Biotech-Biotech Collaborations: Modified Agreements: June 1 - July 15, 2011.  // BioWorld Insight;7/18/2011, Vol. 19 Issue 29, p12 

    The article offers information on modified and terminated agreements between biotechnology companies from June 1 to July 15, 2011. Medivir AB and Meda AB has revised agreement that cover the commercialization of cold sore product Xerese in the U.S., Canada and Mexico. Seattle Genetics and...

  • Back on target. Webb, Sarah // Nature Biotechnology;Mar2013, Vol. 31 Issue 3, p191 

    The article discusses the clinical development of antibody-drug conjugates (ADCs). It states that advancements of technology platforms that facilitate the facile design of antibodies depict the development of new ADCs. Moreover, it provides data on the partnerships of various companies for the...

  • MANUFACTURERS INDEX.  // Monthly Prescribing Reference;Feb2016, Vol. 32 Issue 2, p304 

    A drug manufacturers index for the February 2016 issue of "Monthly Prescribing Reference" journal is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics